Notoginseng Active Composition, Meal Replacement Powder and Their Applications in Improving Intestinal Microecology and Losing Weight, Lowering Blood Glucose and Lipids

Abstract

The present application discloses a notoginseng active composition, a meal replacement powder, and their applications in improving intestinal microecology and reducing weight, blood sugar, and blood lipid. The notoginseng active composition includes 15 active ingredients and inulinobacillus sporogenes live bacteria powder not less than 100 million / g, with an inhibition rate of α-glucosidase not less than 51.49% and an OARC value not less than 32.60 μmol TE / mL. The meal replacement powder prepared using the notoginseng active composition not only has the effects of reducing blood sugar, blood lipid, and weight on diabetic model mice, with little damage to the organs of mice, but also through the analysis of the intestinal flora of mice, it is found that the meal replacement powder provided in the embodiments of the present application has the effect of increasing the abundance of Firmicutes in the intestines of mice, which is beneficial to the transformation of the intestinal microecology of mice towards a probiotic direction.

Description

Technical Field

[0001] This application relates to the technical field of Panax notoginseng, and particularly to an active composition of Panax notoginseng, a meal replacement powder, and their applications in improving intestinal microecology, weight loss, blood sugar reduction, and lipid reduction. Background Art

[0002] Panax notoginseng is the dried rhizome of Polygonum amplexicaule D. Don var. sinense Hemsl., a plant of the genus Polygonum in the family Polygonaceae, and is a commonly used medicinal material of the Miao and Tujia ethnic groups. According to traditional Chinese medicine theory, it tastes astringent and slightly bitter, and has the effects of promoting blood circulation and relaxing tendons, dispelling stasis and relieving pain, antibacterial and anti-inflammatory, and stopping bleeding and promoting granulation. Clinically, it is used for the treatment of diseases such as traumatic injuries and gastroenteritis. The results of modern pharmacological research have proved that Panax notoginseng has effects such as antifungal, antioxidant, and adjuvant treatment of atherosclerosis. In recent years, literature reports have shown that the active ingredients of Panax notoginseng also play an important role in tumor prevention and treatment. However, at present, the research on the bioactive components and pharmacological effects of Panax notoginseng is still relatively scarce. It is of great practical significance to fully explore the active ingredients of Panax notoginseng for further exploring its more extensive application value. Summary of the Invention

[0003] In view of this, the purpose of this application is to develop an active composition of Panax notoginseng with a broader application prospect, as well as its related products and applications.

[0004] In the first aspect, the embodiments of this application disclose an active composition of Panax notoginseng, which includes resveratrol, phloridzin, quercetin, 6-methoxy-7-hydroxycoumarin, catechin, aucubin, methyl protocatechuate, methyl gallate, n-butyl gallate, 6-O-(E)-caffeoylglucoside, daucosterol, benzoyl-β-D-glucopyranoside, 2,8-triol-1-O-β-D-glucopyranoside, quercetin-3-O-α-D-arabinofuranoside, ferulic acid, and inulinobacillus sporogenes live bacteria powder with a content of not less than 100 million / g.

[0005] In the embodiment of the present application, the Panax notoginseng active composition contains 14.20 - 16.24 wt‰ of resveratrol, 16.48 - 18.16 wt‰ of phloridzin, 12.50 - 13.12 wt‰ of quercetin, 4.69 - 4.95 wt‰ of 6-methoxy-7-hydroxycoumarin, 6.498 - 6.622 wt‰ of catechin, 2.088 - 2.172 wt‰ of aucubin, 1.053 - 1.127 wt‰ of methyl protocatechuate, 0.794 - 0.846 wt‰ of methyl gallate, 0.612 - 0.648 wt‰ of n-butyl gallate, 0.415 - 0.445 wt‰ of 6-O-(E)-caffeoylglucoside, 1.732 - 1.848 wt‰ of daucosterol, 12.19 - 14.31 wt‰ of benzoyl-β-D-glucopyranoside, 3.68 - 4.56 wt% of 2,8-triol-1-O-β-D-glucopyranoside, 5.153 - 5.327 wt‰ of quercetin-3-O-α-D-arabinofuranoside and 9.23 - 10.87 wt‰ of ferulic acid, as well as live Bacillus sporolactis powder with not less than 100 million viable bacteria per gram.

[0006] In the embodiment of the present application, the Panax notoginseng active composition contains 11.93 - 14.61 wt‰ of resveratrol, 17.41 - 20.69 wt‰ of phloridzin, 9.18 - 11.08 wt‰ of quercetin, 1.87 - 2.75 wt‰ of 6-methoxy-7-hydroxycoumarin, 4.108 - 5.212 wt‰ of catechin, 1.732 - 1.788 wt‰ of aucubin, 0.745 - 0.775 wt‰ of methyl protocatechuate, 0.317 - 0.363 wt‰ of methyl gallate, 0.449 - 0.491 wt‰ of n-butyl gallate, 0.546 - 0.574 wt‰ of 6-O-(E)-caffeoylglucoside, 1.426 - 1.534 wt‰ of daucosterol, 16.93 - 19.39 wt‰ of benzoyl-β-D-glucopyranoside, 2.89 - 3.61 wt% of 2,8-triol-1-O-β-D-glucopyranoside, 2.732 - 2.848 wt‰ of quercetin-3-O-α-D-arabinofuranoside and 13.56 - 17.14 wt‰ of ferulic acid, as well as live Bacillus sporolactis powder with not less than 100 million viable bacteria per gram.

[0007] In the embodiments of the present application, the active composition of Panax notoginseng contains, by weight per thousand, 14.02 - 16.26 wt‰ of resveratrol, 12.21 - 14.69 wt‰ of phloridzin, 10.19 - 11.97 wt‰ of quercetin, 4.42 - 4.94 wt‰ of 6-methoxy-7-hydroxycoumarin, 7.744 - 7.896 wt‰ of catechin, 2.799 - 2.861 wt‰ of aucubin, 1.189 - 1.311 wt‰ of methyl protocatechuate, 0.817 - 1.003 wt‰ of methyl gallate, 0.738 - 0.782 wt‰ of n-butyl gallate, 0.519 - 0.5761 wt‰ of 6-O-(E)-caffeoylglucoside, 1.448 - 1.612 wt‰ of daucosterol, 9.52 - 11.94 wt‰ of benzoyl-β-D-glucopyranoside, 4.07 - 4.77 wt% of 2,8-triol-1-O-β-D-glucopyranoside, 5.053 - 5.187 wt‰ of quercetin-3-O-α-D-arabinofuranoside, and 9.11 - 10.37 wt‰ of ferulic acid, and viable Bacillus sporolactis powder with no less than 100 million per gram.

[0008] In the embodiments of the present application, the inhibition rate of the active composition of Panax notoginseng against α-glucosidase is not less than 51.49%, and the OARC value is not less than 32.60 μmol TE / mL.

[0009] In the second aspect, the embodiments of the present application disclose a weight loss, blood sugar lowering, and lipid lowering meal replacement powder, which includes 0.0001 - 10 parts of the active composition of Panax notoginseng described in the first aspect, 50 - 80 parts of soluble dietary fiber, and other food-grade acceptable excipients.

[0010] In the third aspect, the embodiments of the present application disclose a preparation method of the active composition of Panax notoginseng described in the first aspect, which includes the following steps:

[0011] Prepare a working seed liquid containing viable Bacillus sporolactis.

[0012] Prepare a seed liquid by inoculating the working seed liquid into a seed medium and culturing at 37°C for 18 h to obtain the seed liquid.

[0013] Prepare a fermentation broth by inoculating the seed liquid into a fermentation medium for culture to obtain the fermentation broth; and

[0014] Concentrate and dry the fermentation broth to obtain the active composition of Panax notoginseng.

[0015] Among them, the seed culture medium contains 2 - 5 g / L of Jerusalem artichoke whole powder, 6 - 20 g / L of pseudo-ginseng powder, 0.1 - 7 g / L of corn flour, and 0.1 - 8 g / L of buckwheat flour; the fermentation culture medium contains 3 - 6 g / L of Jerusalem artichoke whole powder, 8 - 20 g / L of pseudo-ginseng powder, 0.1 - 8 g / L of corn flour, and 0.1 - 8 g / L of buckwheat flour.

[0016] In the embodiment of the present application, the preparation of the working seed liquid is obtained by inoculating activated Lactobacillus sporogenes on a domestication culture medium for domestication culture. The domestication culture medium contains 8 - 18.0 g / L of Jerusalem artichoke whole powder and 2.0 - 12 g / L of pseudo-ginseng powder.

[0017] In the embodiment of the present application, the domestication culture includes sequential domestication cultures in a first domestication culture medium, a second domestication culture medium, and a third domestication culture medium. The first domestication culture medium contains 18.0 g / L of Jerusalem artichoke whole powder and 2.0 g / L of pseudo-ginseng powder. The second domestication culture medium contains 10.0 g / L of Jerusalem artichoke whole powder and 10.0 g / L of pseudo-ginseng powder. The third domestication culture medium contains 8.0 g / L of Jerusalem artichoke whole powder and 12.0 g / L of pseudo-ginseng powder.

[0018] Fourthly, the embodiment of the present application discloses the application of the pseudo-ginseng active composition described in the first aspect or the pseudo-ginseng active composition prepared by the preparation method described in the second aspect in the preparation of health products related to weight loss, blood sugar lowering, and lipid lowering.

[0019] Compared with the prior art, the present application has at least the following beneficial effects:

[0020] The present application uses Lactobacillus sporogenes to ferment pseudo-ginseng powder to prepare a freeze-dried powder containing live Lactobacillus sporogenes and pseudo-ginseng-related hypoglycemic and lipid-lowering active ingredients. Through the analysis of the active ingredients in the freeze-dried powder, it is found that by using the fermentation method of the present application, not only can the content of pseudo-ginseng-related hypoglycemic and lipid-lowering active ingredients be fully increased and enriched, but also these effective ingredients can be comprehensively enriched, providing an application prospect for it to be used as a health product that plays a role in lowering blood sugar and lipid and effectively losing weight.

[0021] Therefore, the embodiment of the present application further uses the freeze-dried powder to make a meal replacement powder, and through in vivo experiments, it is confirmed that the meal replacement powder has the effects of lowering blood sugar and lipid and losing weight on KK / Upj-Ay / J diabetic model mice, has little damage to the organs of mice, has no obvious toxic and side effects, and through the analysis of the intestinal flora of mice, it is found that the meal replacement powder provided by the embodiment of the present application has the effect of increasing the abundance of the Firmicutes phylum in the intestines of mice, and uses the intestinal microecology of mice to shift towards a beneficial direction. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 It is the change of pH value during the fermentation process of Examples 1 - 3 and Comparative Examples 1 - 6 of the present application.

[0023] Figure 2 Staining map of adipocyte sections of normal group mice provided for in vivo experiments of this application.

[0024] Figure 3 Staining map of adipocyte sections of model group mice provided for in vivo experiments of this application.

[0025] Figure 4 Staining map of adipocyte sections of intervention group (Example 1) mice provided for in vivo experiments of this application.

[0026] Figure 5 Staining map of adipocyte sections of positive control group (Example 1) mice provided for in vivo experiments of this application. Detailed implementation manners

[0027] In order to make the objectives, technical solutions and advantages of this application clearer, the following further describes this application in detail with reference to examples. It should be understood that the specific examples described herein are only used to explain this application and are not used to limit this application.

[0028] Probiotic fermentation

[0029] I. Materials and methods

[0030] 1. Biological materials

[0031] Notoginseng, dry goods, ground into powder, from Wenshan Fuwanjia.

[0032] Auxiliary materials: Buckwheat flour was purchased from Xinghua Yufeng Food Co., Ltd., and corn flour was purchased from Xi'an Clover Biotechnology Co., Ltd.

[0033] Sporolactobacillus inulinus (abbreviated as SI), product number B81253, purchased from Mingzhou Biology.

[0034] 2. Preparation of working seed liquid

[0035] The freeze-dried powder of Sporolactobacillus inulinus was activated using glucose yeast extract peptone (GYP) medium. The first activation of the freeze-dried powder should be used up completely. 0.5 mL of the above-mentioned culture solution was used for dissolution and inoculated onto a solid GYP plate. After culturing at 33 °C for 15 - 18 h, single colonies were picked and inoculated onto the acclimation medium for acclimation culture.

[0036] During the implementation process of the specific Example 1, the domestication culture includes the step of inoculating the activated SI colony into the first domestication medium for domestication; a specific example of the formula of the first domestication medium is as follows: casein digest 10.0 g, beef extract powder 15.0 g, ammonium citrate 2.0 g, sodium acetate 5.0 g, manganese sulfate 0.05 g, magnesium sulfate 0.2 g, dipotassium hydrogen phosphate 2.0 g, Jerusalem artichoke whole powder 18.0 g, notoginseng powder 2.0 g, 1.5 g α-amylase (Xiasheng FDY-2801), 1.2 g β-amylase (Xiasheng FDG-2258), 1 mL Tween, add distilled water to 1000 mL, boil and dissolve, adjust the pH to 7.0 (20-25 °C), sterilize at 121 °C for 20 min, after cooling and aliquoting, inoculate the activated SI single colony into the domestication medium at an inoculation amount of 12 wt%, and culture at 36 °C for 15-18 h, then the working seed liquid can be obtained.

[0037] During the implementation process of the specific Example 2, the steps of the domestication culture include the step of successively transferring the active SI colony to the first, second, and third domestication media for culture; the second domestication medium contains 10.0 g / L Jerusalem artichoke whole powder and 10.0 g / L notoginseng powder, and the remaining components are the same as those of the first domestication medium, the inoculation amount is 10 wt%, and after culturing at 38 °C for 15-18 h; then transfer it to the third domestication medium again, the third domestication medium contains 8.0 g / L Jerusalem artichoke whole powder and 12.0 g / L notoginseng powder, and the remaining components are the same as those of the first domestication medium, the inoculation amount is 10 wt%, and after culturing at 38 °C for 15-18 h, the working seed liquid can be obtained.

[0038] During the implementation process of the specific Comparative Example 1, the relevant domestication culture steps were not carried out, but the activated SI colony was directly inoculated into the working seed medium. A specific formula of the working seed medium used in Comparative Example 1 includes 20 g / L glucose, 10 g / L peptone, 10 g / L beef extract, 5 g / L yeast extract, 2 g / L diammonium hydrogen citrate, 5 g / L sodium acetate, 2 g / L dipotassium hydrogen phosphate, 0.25 g / L manganese sulfate, 0.5 g / L magnesium sulfate, 1 mL Tween 80, pH 6.4, sterilize at 121 °C for 15 min, culture at 40 °C for 16 h, and make the OD600 value of the working seed bacterial liquid reach above 0.2.

[0039] 3. Preparation of seed liquid and fermentation liquid

[0040] The working seed liquors prepared in Example 1, Example 2 and Comparative Example 1 above were respectively inoculated into the seed medium and cultured at 37°C for 18 h. A specific seed medium formulation includes: 25.0 g of beef extract powder, 3.0 g of whole Jerusalem artichoke powder, 12.0 g of notoginseng powder, 5.0 g of corn flour, 7.0 g of buckwheat flour, 2.0 g of ammonium citrate tribasic, 5.0 g of sodium acetate, 0.05 g of manganese sulfate, 0.2 g of magnesium sulfate, 2.0 g of dipotassium hydrogen phosphate, 1 mL of Tween, add distilled water to 1000 mL, boil and dissolve, adjust the pH to 7.0 (20 - 25°C), sterilize at 121°C for 20 min. After cooling and dispensing, the working seed liquor was inoculated into the seed medium at an inoculation amount of 12 wt%, and cultured at 36°C for 15 - 18 h to obtain the seed liquor.

[0041] The seed liquor was inoculated into the fermentation medium at an inoculation amount of 8 wt% for culture to obtain the fermentation liquor. A specific fermentation medium formulation includes: 20.0 g of beef extract powder, 5.0 g of whole Jerusalem artichoke powder, 15.0 g of notoginseng powder, 8.0 g of corn flour, 10.0 g of buckwheat flour, 2.0 g of ammonium citrate tribasic, 5.0 g of sodium acetate, 0.05 g of manganese sulfate, 0.2 g of magnesium sulfate, 2.0 g of dipotassium hydrogen phosphate, 1 mL of Tween, add distilled water to 1000 mL, boil and dissolve, sterilize at 121°C for 20 min, and then transfer to a fermentation tank after cooling. No sterile air was introduced in the early stage of fermentation at 40°C. As the cell concentration (OD600 value increased), the redox potential and carbon dioxide changed. After 4 h of culture, it was transferred to the micro-aerobic culture stage, and the sterile air flow rate was controlled according to the changes in redox potential and carbon dioxide. During the fermentation from 4 - 30 h, the redox potential was controlled at -150 mV to -180 mV, and the tail gas carbon dioxide content was controlled at 15% to 20%. After 30 h of fermentation, no sterile air was introduced anymore, and the fermentation ended after 56 h.

[0042] The implementation process of Example 3 is as follows: The working seed liquor used is the same as the working seed liquor prepared in Example 1, but the formulations of the seed medium and fermentation medium in the experiment are both: 25.0 g of beef extract powder, 3.0 g of whole Jerusalem artichoke powder, 12.0 g of notoginseng powder, 5.0 g of corn flour, 7.0 g of buckwheat flour, 2.0 g of ammonium citrate tribasic, 5.0 g of sodium acetate, 0.05 g of manganese sulfate, 0.2 g of magnesium sulfate, 2.0 g of dipotassium hydrogen phosphate, 1 mL of Tween, add distilled water to 1000 mL.

[0043] The implementation process of a comparative example 2 is as follows: The working seed liquid used is the same as the working seed liquid prepared in Example 1, but the formulations of the seed medium and the fermentation medium in the experiment are both: 20 g / L glucose, 10 g / L peptone, 10 g / L beef extract, 5 g / L yeast extract, 2 g / L diammonium hydrogen citrate, 5 g / L sodium acetate, 2 g / L dipotassium hydrogen phosphate, 0.25 g / L manganese sulfate, 0.5 g / L magnesium sulfate, 1 mL Tween 80, pH 7.0, sterilized at 121 °C for 15 min, and cultured at 40 °C for 56 h; thus, the fermentation broth is obtained through fermentation.

[0044] The implementation process of a comparative example 3 is as follows: The working seed liquid used is the same as the working seed liquid prepared in Example 2, but the formulations of the seed medium and the fermentation medium used are both: 20 g / L glucose, 10 g / L peptone, 10 g / L beef extract, 5 g / L yeast extract, 2 g / L diammonium hydrogen citrate, 5 g / L sodium acetate, 2 g / L dipotassium hydrogen phosphate, 0.25 g / L manganese sulfate, 0.5 g / L magnesium sulfate, 1 mL Tween 80, pH 7.0, sterilized at 121 °C for 15 min, and cultured at 40 °C for 56 h; thus, the fermentation broth is obtained through fermentation.

[0045] The implementation process of a comparative example 4 is as follows: The working seed liquid used is the same as the working seed liquid prepared in Comparative Example 1, but the formulations of the seed medium and the fermentation medium in the experiment are both: 20 g / L glucose, 10 g / L peptone, 10 g / L beef extract, 5 g / L yeast extract, 2 g / L diammonium hydrogen citrate, 5 g / L sodium acetate, 2 g / L dipotassium hydrogen phosphate, 0.25 g / L manganese sulfate, 0.5 g / L magnesium sulfate, 1 mL Tween 80, pH 7.0, sterilized at 121 °C for 15 min, and cultured at 40 °C for 56 h; thus, the fermentation broth is obtained through fermentation.

[0046] The implementation process of a comparative example 5 is as follows: The working seed liquid used is the same as the working seed liquid prepared in Example 1, but the formulations of the seed medium and the fermentation medium in the experiment are both: 25.0 g beef extract powder, 3.0 g Jerusalem artichoke whole powder, 20.0 g glucose powder, 2.0 g ammonium citrate, 5.0 g sodium acetate, 0.05 g manganese sulfate, 0.2 g magnesium sulfate, 2.0 g dipotassium hydrogen phosphate, 1 mL Tween, add distilled water to 1000 mL, adjust pH 7.0, sterilized at 121 °C for 15 min, and cultured at 40 °C for 16 h; thus, the fermentation broth is obtained through fermentation.

[0047] The implementation process of a comparative example 6 is as follows: The working seed liquid used is the same as the working seed liquid prepared in Example 1, but the formulas of the seed culture medium and the fermentation culture medium for the experiment are both: 25.0 g of beef extract powder, 5.0 g of corn flour, 7.0 g of buckwheat flour, 2.0 g of ammonium citrate, 5.0 g of sodium acetate, 0.05 g of manganese sulfate, 0.2 g of magnesium sulfate, 2.0 g of dipotassium hydrogen phosphate, 1 mL of Tween, add distilled water to 1000 mL, adjust the pH to 7.0, sterilize at 121 °C for 15 min, and culture at 40 °C for 16 h; thus, the fermentation broth is obtained through fermentation.

[0048] 4. Determination of related indicators

[0049] Collect the fermentation broths provided in Examples 1 to 3 and Comparative Examples 1 to 6 and conduct the following determinations of related indicators.

[0050] Determination of the viable counts of lactic acid bacteria and yeasts: The dilution pour plate method is adopted, referring to the method for the determination of the total number of yeast and lactic acid bacteria colonies in GB 4789-2010.

[0051] pH determination: The pH of the fermented liquid mulberry pulp is directly measured with a PB-10 pH meter.

[0052] Determination of antioxidant capacity: The ORAC of the fermentation broths prepared in the above-mentioned examples and comparative examples is determined by the Oxygen Radical Absorbance Capacity (ORAC) method, and the results are expressed in μmol TE / mL (μmol TE / g).

[0053] The measurement method is as follows: Add 20 μL of the diluted sample solution and the Trolox standard solution (Wako Pure Chemical Industries, Ltd., Japan) into the micro-wells of a 96-well plate respectively, then add 80 μL of 1.25 μmol / L sodium fluorescein solution (prepared with 75 mmol / L phosphate buffer solution with a pH of 7.4), mix evenly, and react in the dark at 37 °C for 10 min; then add 100 μL of 140 mmol / L free radical generator AAPH (prepared with 75 mmol / L phosphate buffer solution with a pH of 7.4), after mixing, place the micro-well plate in an enzyme-labeling instrument, and perform multi-point cyclic measurement at an excitation wavelength of 485 nm and an emission wavelength of 520 nm at 37 °C. Measure the fluorescence intensity of each micro-well every 2 min, and the measurement time is generally set until the fluorescence decay shows a baseline. The experiment is divided into negative control group 1, negative control group 2, and experimental group. The free radical generator AAPH is not added to the micro-wells of the negative control group 1. The Trolox standard solution is not added to the micro-wells of the negative control group 2. The antioxidant capacity of the sample is directly related to the area of the delayed part (Net AUC) of the fluorescence decay curve under the action of free radicals. After the fluorescence intensity data of each micro-well reaction obtained from the experiment are output by the software, they are statistically processed by SPSS. The absolute fluorescence intensity data at different time points of each well are compared with the fluorescence intensity of the negative control group 1, and converted into relative fluorescence intensity f. The area under the curve (AUC) of the quenching curve is calculated by the approximate integration method using the relative fluorescence intensity. Then, the OARC value = [(AUC 样品 - AUC 阴性对照组2 ) / (AUC 标准品 - AUC 阴性对照组2 )] × (amount of Trolox standard solution / amount of sample).

[0054] Determination of α-glucosidase inhibition rate: Take 50 μL of the sample (the fermentation broth provided by each example and comparative example) in a 96-well sterile cell plate, and add 100 μL of 0.1 M phosphate buffer solution with a pH of 6.9 containing 1 u / mL α-glucosidase (G5003-100UN). After reacting at 25 °C for 10 min, continue to add 50 μL of 0.1 M phosphate buffer solution with a pH of 6.9 containing 1.5 mM p-nitrophenyl-α-D-glucopyranoside. After mixing evenly, immediately measure the absorbance value at 405 nm with an enzyme-labeling instrument. Use the well plate with 50 μL of 0.1 M phosphate buffer solution with a pH of 6.9 as the blank control, and calculate the α-glucosidase inhibition rate (%) according to the formula = (1 - A sample / A blank) × 100%.

[0055] Determination of monosaccharide content: The sample to be tested (the fermentation broth provided in each example and comparative example) was added with anhydrous ethanol with a volume twice that of the sample, ultrasonically treated for 30 min, centrifuged at 8000 rpm for 10 min, and filtered through a 0.22-μm filter membrane for HPLC analysis of the monosaccharide content. The chromatographic conditions were as follows: a high-performance liquid chromatography column for sugar analysis (4.6 mm × 250 mm, 5 μm, Cosmosil Sugar-D), column temperature of 30 °C, detected by an evaporative light scattering detector with an ELSD drift tube temperature of 40 °C; the mobile phase was 75% acetonitrile, flow rate of 1 mL / min, injection volume of 10 μL; the external standard method was used for quantitative analysis of the monosaccharide content.

[0056] Determination of organic acid content: A certain amount of metaphosphoric acid solution was used to extract the sample, ultrasonically treated for 30 min, centrifuged at 8000 rpm for 10 min, the supernatant was taken, filtered through a 0.22-μm filter membrane, and used for HPLC analysis. The chromatographic conditions were as follows: Aquasil C18 chromatographic column (4.6 mm × 250 mm, 5 μm); the mobile phase was 0.1% ammonium dihydrogen phosphate with a pH of 2.7, isocratic elution for 15 min, flow rate of 1 mL / min, injection volume of 20 μL, detection wavelength of 210 nm. The external standard method was used to determine the organic acid content.

[0057] 5. Data processing

[0058] All test data were expressed as mean and standard deviation. The data were processed using SPSS 13.0 software, and multiple comparisons and significant difference markers were performed on each column of data.

[0059] II. Results

[0060] Table 1

[0061]

[0062] As can be seen from Table 1, the viable cell counts of Lactobacillus inulinus in the fermentation broths provided in Examples 1 to 3 were significantly higher than those in Comparative Examples 1 to 6 (except Comparative Example 4). This indicates that the fermentation method provided in the embodiments of the present application can provide a fermentation broth with a higher viable cell count. In Table 1, "-" indicates not detected. And from Figure 1 it can be seen that during the fermentation process from 0 to 56 h, in the fermentation processes of Examples 1 to 3, during the process from 0 to 12 h, the fermentation pH value decreased rapidly, and after 36 h of fermentation, the pH value of the fermentation broth was relatively stable; while except for Comparative Example 4, the pH values of the fermentation broths of other comparative examples gradually decreased during the fermentation process, and the pH values of the fermentation broths after fermentation were all lower than those of the examples. In addition, as can be seen from Table 1, the organic acid content in the final fermentation broths obtained in Examples 1 to 3 was relatively low; while the organic acid content in the final fermentation broths obtained in Comparative Examples 1 to 3 was relatively high, acetic acid and citric acid were not detected in the fermentation broth provided in Comparative Example 4, and the organic acid content in Comparative Examples 5 and 6 was comparable to that of the examples.

[0063] Table 2

[0064]

[0065]

[0066] Table 2 lists the fructose and glucose contents in each fermentation broth, as well as the OARC values and α-glucosidase inhibition rates of each fermentation broth. In Table 2, "-" indicates not detected. The results show that the fructose and glucose contents in the fermentation broths provided in Examples 1 to 3 are significantly lower than those in Comparative Examples 1 to 6, and even the monosaccharide components were not detected in Example 3. Thus, it is shown that the fermentation broths provided in the examples of the present application are fermentation broths with low sugar content.

[0067] Furthermore, as can be seen from Table 2, the OARC values and α-glucosidase inhibition rates of the fermentation broths provided in Examples 1 to 3 are significantly higher than those in the comparative examples. Thus, it is shown that the inulinobacillus capsulatus fermentation broth provided in the examples of the present application has excellent antioxidant and α-glucosidase inhibition functions.

[0068] Analysis of active ingredients in fermentation broth

[0069] 1. Post-treatment of the fermentation broth

[0070] (1) Extract

[0071] Collect the fermentation broths prepared in Examples 1 to 3 and Comparative Examples 1 to 6 above, and after concentration under reduced pressure at 65°C, add them to 9 times the volume of 95% aqueous ethanol solution, stir magnetically for 30 min, centrifuge at 2000 rpm for 10 min, take the supernatant and concentrate it under reduced pressure to obtain the first extract.

[0072] (2) Extraction

[0073] Dissolve the extract in 90% methanol and extract it 3 to 5 times with an equal volume of petroleum ether, take the lower layer phase, and recover it under reduced pressure to obtain the second extract;

[0074] Extract the second extract with isobutanol, propanol, tetrahydrofuran, and acetone in sequence, and use the lower layer extract or solution after each extraction as the material to be extracted in the next stage.

[0075] Thus, isobutanol extract, propanol extract, tetrahydrofuran extract, and acetone extract are obtained in sequence. These extracts are concentrated under reduced pressure and freeze-dried respectively to remove the solvents therein, and the corresponding lyophilized powders are obtained.

[0076] 2. Detection of active ingredients in the lyophilized powder

[0077] The isobutanol extract and propanol extract were detected by reverse-phase liquid chromatography using a Waters Sunfire ODS C18 column (250 mm × 4.6 mm, 5 μm) as the chromatographic column, with acetonitrile-water as the mobile phase, gradient elution, a flow rate of 1.0 ml / min, a detection wavelength of variable wavelength (0 min, 230 nm; 10 min, 283 nm; 25 min, 203 nm), a column temperature of 30 °C, and an injection volume of 10 μL.

[0078] Test samples: The lyophilized powders of the above-mentioned isobutanol extract, propanol extract, tetrahydrofuran extract, and acetone extract were respectively dissolved in the corresponding isopropanol, propanol, tetrahydrofuran, and acetone as solvents to prepare a 1.0 mg / mL solution as the test samples.

[0079] Reference standards: The reference standards involved in this experiment are shown in Table 3.

[0080] Table 3 Reference Standards

[0081]

[0082] 3. Results

[0083] Table 4

[0084]

[0085]

[0086] Table 4 lists the lyophilized powders of the isobutanol extract, propanol extract, tetrahydrofuran extract, and acetone extract obtained by post-treating the fermentation broths obtained from Examples 1 to 3 and Comparative Examples 1 to 6 through the above fermentation method. After mixing these lyophilized powders, the weight percentages of H1 - H15 in the lyophilized powder of the fermentation broth were detected by the above reverse-phase chromatography method, and "wt‰" represents parts per thousand by weight. In addition, in this application, the powder of Panax notoginseng was directly used as Comparative Example 7, and through the above steps of extract and extraction, the lyophilized powders of the isobutanol extract, propanol extract, tetrahydrofuran extract, and acetone extract were obtained. After mixing these lyophilized powders, the weight percentages of the compounds H1 - H15 in the powder of Panax notoginseng were detected by the above reverse-phase chromatography method. In Table 4, the components not specified for the compounds H1 - H15 represent that the compound was not detected.

[0087] As can be seen from Table 4, compared with Comparative Example 7, in Examples 1 to 3, not only are the components of H1 - H15 completely retained, but also their content ratios have increased by 3 data levels, greatly enriching the relevant active components in Panax notoginseng.

[0088] In Comparative Examples 1 and 4, since the working seed liquid prepared in Comparative Example 1 was used in the fermentation process, a large amount of the active ingredients related to Panax notoginseng in the freeze-dried powder of the extract was lost after the post-treatment of the fermentation broth. In Comparative Examples 2, 3, and 6, due to the different medium formulations in the fermentation process, a large amount of the active ingredients related to Panax notoginseng in the freeze-dried powder of the extract was also lost after the post-treatment of the fermentation broth. The relevant active ingredients of Panax notoginseng in the freeze-dried powder of the extract prepared in Comparative Example 5 were retained.

[0089] In vivo experiments

[0090] I. Materials and Methods

[0091] 1. Experimental animals

[0092] SPF-grade KK / Upj-Ay / J diabetic model mice, weighing 24.5 ± 2.3 g, with half males and half females, were fed 60 Co mouse feed 1025, supplied by Guangzhou Saibenuo Biotechnology Co., Ltd.

[0093] SPF-grade C56BL / 6J mice, weighing 20.1 ± 1.6 g, with half males and half females, were fed normally, supplied by Beijing Huafukang Biotechnology Co., Ltd.

[0094] The experimental animals were housed in IVC cages at a temperature of 21 - 25 °C and a humidity of 40 - 70%. The diabetic model mice were fed a special high-fat and high-energy diet 60 Co mouse feed 1025, and the C57BL / 6J mice were fed SPF special feed, both purchased from Beijing Huafukang Biotechnology Co., Ltd.

[0095] 2. Test articles

[0096] In this experiment, a meal replacement powder was prepared based on the above Examples 1 - 3 and Comparative Examples 1 - 7 to test its hypoglycemic, lipid-lowering, and weight loss effects on model mice. The specific preparation process can be referred to as follows:

[0097] All the basic raw materials were ball-milled to the specified particle size, passed through a 100-mesh sieve, and then, using the dilution process technology, the soluble dietary fiber component, the freeze-dried powder provided by Examples 1 - 3 or Comparative Examples 1 - 7, and other excipients were pre-mixed in a three-dimensional mixer to obtain the meal replacement powder.

[0098] Therefore, the embodiments of this application also disclose a meal replacement powder with hypoglycemic, lipid-lowering, and weight loss functions, which includes 0.0001 - 10 powders of the freeze-dried powder prepared in the above Examples 1 - 3, 50 - 80 parts of soluble dietary fiber, and other food-grade acceptable excipients.

[0099] Among them, the freeze-dried powders prepared in Examples 1 to 3 are obtained by concentrating and freeze-drying the fermentation broth prepared by fermentation in Examples 1 to 3. During the freeze-drying process, a freeze-drying protectant with a weight percentage not greater than 6 wt% can be added. Specifically, the freeze-drying protectant is selected from at least one of skim milk, sucrose, trehalose, dextran, and sodium ascorbate.

[0100] Among the components of the above meal replacement powder, the soluble dietary fiber is selected from at least one of water-soluble soybean dietary fiber, water-soluble brown rice fiber, water-soluble germ polished rice fiber, water-soluble corn fiber, water-soluble barley fiber, water-soluble rice bran fiber, water-soluble root vegetable fiber, water-soluble kelp fiber, water-soluble carrot fiber, water-soluble four-season fiber, water-soluble adzuki bean fiber, water-soluble pea fiber, water-soluble sweet potato fiber, and water-soluble wakame fiber.

[0101] Among the components of the above meal replacement powder, the food-acceptable excipients include flavoring agents, flavor enhancers, and / or food preservatives.

[0102] Specifically, the formula of the meal replacement powder of the test article involved in this experiment is shown in Table 5.

[0103] Table 5

[0104] Embodiment Formulation Example 1 8 parts of freeze-dried fermentation powder, 65 parts of soluble dietary fiber, 0.5 part of sodium L-glutamate Example 2 8 parts of freeze-dried fermentation powder, 65 parts of soluble dietary fiber, 0.5 part of sodium L-glutamate Example 3 8 parts of freeze-dried fermentation powder, 65 parts of soluble dietary fiber, 0.5 part of sodium L-glutamate Comparative Example 1 8 parts of freeze-dried fermentation powder, 65 parts of soluble dietary fiber, 0.5 part of sodium L-glutamate Comparative Example 2 8 parts of freeze-dried fermentation powder, 65 parts of soluble dietary fiber, 0.5 part of sodium L-glutamate Comparative Example 3 8 parts of freeze-dried fermentation powder, 65 parts of soluble dietary fiber, 0.5 part of sodium L-glutamate Comparative Example 4 8 parts of freeze-dried fermentation powder, 65 parts of soluble dietary fiber, 0.5 part of sodium L-glutamate Comparative Example 5 8 parts of freeze-dried fermentation powder, 65 parts of soluble dietary fiber, 0.5 part of sodium L-glutamate Comparative Example 6 8 parts of freeze-dried fermentation powder, 65 parts of soluble dietary fiber, 0.5 part of sodium L-glutamate Comparative Example 7 8 parts of powder of Panax notoginseng, 65 parts of soluble dietary fiber, 0.5 part of sodium L-glutamate

[0105] 3. Experimental grouping

[0106] After 1 week of adaptive feeding, the experiment was started. C57BL / 6J mice were set as the normal control group. KK / Upj-Ay / J diabetic model mice with blood glucose values reaching the diabetes diagnosis standard (i.e., ≥ 11.1 mmol / L) were randomly divided into a model group, an intervention group, and a positive group according to random blood glucose levels, with 20 animals in each group, half male and half female.

[0107] The intervention group was given the above test article by gavage twice a day, with a dosing volume of 20 mg / kg.bw and a gavage volume of 0.1 mL / 10 g, with an interval of more than 4 h, and continuously administered for 4 weeks.

[0108] The dose of metformin hydrochloride given to the mice in the positive group was: 128 mg / kg.bw in the first week, 204 mg / kg.bw in the second week, 280 mg / kg.bw in the third week, and 303 mg / kg.bw from the fourth week to the end of the experiment, with a gavage volume of 0.1 mL / 10 g.

[0109] The normal control group and the model group were given an equal volume of 0.5% sodium carboxymethylcellulose. The temperature in the mouse house was maintained at 20 - 24 °C, with 12 h of day and night each, and the relative humidity was about 60 - 65%. The experiment was carried out for 4 weeks.

[0110] 4. Body weight and blood glucose monitoring

[0111] Weigh once a week. During the blood glucose administration period, measure the random blood glucose and fasting blood glucose once a week. Fast for 4 hours without restricting water intake before measuring the fasting blood glucose. Wipe the mouse tail tip clean with an alcohol cotton ball, take about 2 μL of blood and drop it on the blood glucose test strip to detect the blood glucose value.

[0112] 5. Detection of four lipid items, insulin, glycated hemoglobin, and histopathological examination

[0113] After 4 weeks of administration, the mice were fasted for 16 hours without restricting water intake, then blood was collected by eye socket enucleation. After natural coagulation, the serum was separated by centrifugation at 3000 rpm for 10 minutes. Use a biochemical analyzer (AU5800 series, BECKMAN) to detect four indicators of total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C). Use an INS ELISA kit (product number: JL18382, Jianglai Biotech) to detect the insulin content, and a glycated hemoglobin ELISA kit (Shanghai Yiyan Biotechnology Co., Ltd.) to detect the glycated hemoglobin content. And calculate the insulin sensitivity index (ISI). ISI is the reciprocal of the product of the fasting blood glucose value and the fasting blood insulin value, showing a non-normal distribution. Take its natural logarithm value during analysis.

[0114] Put the epididymal fat of the appropriate size of the testicular appendage of the mice in each group into a fat fixing solution bottle for fixation. Take a 1 cm square block from the middle of the largest lobe of the liver of the liver tissue and put it into a neutral formaldehyde fixing solution bottle for fixation. The fixation time is 24 hours. Make paraffin sections, and after hematoxylin staining, observe under an optical fiber microscope.

[0115] Data analysis: All test data are expressed as the mean and standard deviation. Use SPSS13.0 software to process the data, and perform multiple comparisons and significant difference markings on each column of data.

[0116] 6. Effects on the intestinal flora of mice

[0117] (1) Collect the feces of mice in each group, and extract genomic DNA from the samples using the CTAB method; then perform DNA amplification. The amplification primers are F: cctaygggrbgcascag; R: ggactacnngggtatctaat. After the amplification products are detected by agarose gel electrophoresis, the target bands are recovered, and the mixed PCR products are purified using the genejettmgel extraction kit (Thermo Scientific). Use the Ion Plus Fragment Library Kit 48rxns from Thermofisher to construct the library. After quantitative analysis by Qubit and library qualification detection, the IonSSTMXL from Thermofisher is used for on-machine sequencing.

[0118] (2) Data analysis

[0119] First, apply Cutadapt (V1.9.1, http: / / cutadapt.readthedocs.io / en / stab / ) to shear the low-quality parts of the reads, obtain the data of each sample split from the reads according to the Barcode, and intercept the raw data obtained from the preliminary quality control (Raw reads). After the Reads are processed as above, the step of removing chimeric sequences is still required. This sequence is compared with the species annotation database through (https: / / github.com / torognes / vsearch / ) to remove the chimeric sequences therein, and finally the final effective data (Clean Reads) are obtained.

[0120] The Clean Reads of all samples were clustered using the Uparse software (Uparse v7.0.1001, http: / / www.drive5.com / uparse / ), with 97% identity as the default value, and the sequences were clustered into OTUs (Operational Taxonomic Units). At the same time, the representative sequences of the OTUs were selected. According to the algorithm principle, the representative sequence of the OTUs is the sequence with the highest occurrence frequency. The OTU sequences were analyzed for species annotation using the Mothur method and the method of the SSUrRNA database of SILVA132 (http: / / www.arb-silva.de / ) (setting the threshold value to 0.8 - 1). After finally obtaining the taxonomic information, the community compositions of each sample were statistically analyzed: kingdom, phylum, class, order, family, genus, species. Fast multiple sequence alignment was performed using the MUSCLE (Version3.8.31, http: / / www.drives.com / muscle / ) software. Finally, the data of each group of samples were normalized with the sample with the least amount of data as the standard.

[0121] The Qiime software (Version 1.9.1) was used to calculate Observed-species and Chaol, and the R software (Version2.15.3) was used for analysis. The diversity analysis was used to evaluate the complexity of species differences between samples.

[0122] II. Results

[0123] Table 6

[0124]

[0125] As can be seen from Table 6, the body weight and random blood glucose of the mice in the model group were significantly increased after the 4th week of the experiment. Although the random blood glucose of the mice in the positive control group was significantly lower than that of the model group, its body weight was not significantly reduced, indicating that it has no weight loss effect on the model mice. In the intervention group, after the meal replacement powder provided in Examples 1 - 3 was used to intervene in KK / Upj-Ay / J diabetic model mice for 4 weeks, their body weight and random blood glucose were significantly lower than those of the model group and the positive control group, and were not much different from those of the normal group. This shows that the meal replacement powder prepared based on the fermented freeze-dried powder of Panax notoginseng fermented by probiotics in the embodiments of the present application has hypoglycemic and weight loss effects on KK / Upj-Ay / J diabetic model mice.

[0126] Table 7

[0127]

[0128] As can be seen from Table 7, the four blood lipids of the mice in the model group were significantly increased after the 4th week of the experiment. Although the random blood glucose of the mice in the positive control group was significantly lower than that of the model group, it was still significantly higher than that of the normal group, indicating that the lipid-lowering effect of the positive drug on the model mice was limited. In the intervention group, after the meal replacement powder provided in Examples 1 to 3 was used to intervene in KK / Upj-Ay / J diabetic model mice for 4 weeks, the four blood lipids were significantly lower than those of the model group and the positive control group, and there was little difference from the normal group. Thus, it shows that the meal replacement powder prepared based on the freeze-dried powder of fermented Panax notoginseng fermented by probiotics in the embodiments of the present application has a lipid-lowering effect on KK / Upj-Ay / J diabetic model mice.

[0129] Furthermore, by detecting the organ index and fat index of the mice to comprehensively reflect the effects of drug intervention on the health status and body fat content of the mice, the results are shown in Table 8.

[0130] Table 8

[0131]

[0132] As can be seen from Table 8, the BMI index, Lee's index, white fat index and liver index of the mice in the model group were all significantly higher than those of the normal group, indicating that the mice in the model group not only had symptoms of hyperglycemia, hyperlipidemia and obesity, but also had the possibility of liver damage. In the intervention group, after the meal replacement powder provided in Examples 1 to 3 was used to intervene in the mice, their BMI index, Lee's index, white fat index and liver index were all significantly reduced, especially the white fat index. Thus, it shows that the meal replacement powder provided in the embodiments of the present application not only has the effects of reducing blood sugar and blood lipids and losing weight, but also has less damage to the organs of the mice.

[0133] In addition, as Figure 2 shown, the fat of normal mice is arranged orderly and has regular shapes, while the fat cells of the model group are arranged disorderly, with different sizes, and the fat cells are swollen. Due to the abnormal accumulation of fat, the size of the fat cells can reflect the obesity degree of the body. Figure 3 In terms of the average size of the fat cells, the average fat size of the model group was extremely significantly higher than that of the normal group; Figure 4 , 5 in

[0134] , the intervention group (Example 1) and the positive control both significantly reduced the size of the fat cells of the mice, indicating that the meal replacement powder provided in the examples has a good weight loss effect.

[0135] Table 9 Relative Abundance

[0136]

[0137] Table 10 Relative Abundance

[0138]

[0139]

[0140] As shown in Tables 9 and 10, the intestinal flora is mainly composed of Bacteroidetes (Bac.) and Firmicutes (Fir.), followed by Actinobacteria (Act.), Deferribacteres (Def.), Tenericutes (Tle.), Proteobacteria (Pro.), etc. with relatively small proportions. Among them, Firmicutes mainly includes Lactobacillus (Lac.), Bifidobacterium (Bif.), Blautia (Bla.), Marvinbryantia (Mar.), and Lactobacillus inulinus (S. inulinus) added to the meal replacement powder, etc., all of which are probiotics.

[0141] Moreover, compared with the normal group, in the intestinal flora of the model group mice, the abundance of Firmicutes decreased, especially Bifidobacterium and Blautia among them, and the unidentified Bacteria and Proteobacteria (often pathogenic bacteria) in their intestinal flora increased significantly, indicating that the intestinal microecology of the model group mice has deteriorated and is not conducive to their physiological health. After intervention with the meal replacement powder provided in Examples 1 to 3 of the present application, the abundance of Firmicutes in the mice's flora increased significantly. And after supplementing Lactobacillus inulinus, a certain abundance appeared in their intestinal flora. Although Comparative Example 5 has been proven to have a certain hypoglycemic and lipid-lowering effect through the foregoing experiments, the intestinal abundance of Lactobacillus inulinus in it is far less than that of Examples 1 to 3. This shows that the fermentation medium used in the fermentation of Lactobacillus inulinus in Comparative Example 5 has a significant impact on the viable bacteria count in the prepared freeze-dried fermentation powder and the final effect on the intestinal abundance of mice. After other comparative examples intervened in the mice, the increase in the abundance of Firmicutes was not obvious, which is not conducive to the transformation of the intestinal microecology of mice towards a beneficial direction.

[0142] The above is only the preferred specific implementation manner of the present application, but the protection scope of the present application is not limited thereto. Any changes or substitutions that can be easily thought of by those skilled in the art within the technical scope disclosed by the present application should be covered within the protection scope of the present application.

Claims

1. A Panax notoginseng active composition, wherein the Panax notoginseng is the dried rhizome of Polygonum amplexicaule var. sinense Hemsl. of the genus Polygonum in the family Polygonaceae, and is characterized in that, It is prepared by the following preparation method: Prepare a working seed solution containing viable Bacillus amyloliquefaciens inulin, and the working seed solution is obtained by inoculating activated Bacillus amyloliquefaciens inulin onto a domestication medium for domestication culture; Prepare a seed solution, and the seed solution is obtained by inoculating the working seed solution into a seed medium and culturing at 37°C for 18 h; the seed medium contains 3 g / L Jerusalem artichoke whole powder, 12 g / L notoginseng powder, 5 g / L corn flour and 7 g / L buckwheat flour; Prepare a fermentation broth, and the fermentation broth is obtained by inoculating the seed solution into a fermentation medium for culture; the fermentation medium contains 5 g / L Jerusalem artichoke whole powder, 15 g / L notoginseng powder, 8 g / L corn flour and 10 g / L buckwheat flour; and Concentrate and dry the fermentation broth to obtain the notoginseng active composition; the inhibition rate of the notoginseng active composition against α-glucosidase is not less than 51.49%, and the OARC value is not less than 32.60 μmol TE / mL; Among them, the notoginseng active composition contains 11.93~14.61 wt‰ resveratrol, 17.41~20.69 wt‰ phloridzin, 9.18~11.08 wt‰ quercetin, 1.87~2.75 wt‰ 6-methoxy-7-hydroxycoumarin, 4.108~4.212 wt‰ catechin, 1.732~1.788 wt‰ aucubin, 0.745~0.775 wt‰ methyl protocatechuate, 0.317~0.363 wt‰ methyl gallate, 0.449~0.491 wt‰ n-butyl gallate, 0.546~0.574 wt‰ 6-O-(E)-caffeoylglucoside, 1.426~1.534 wt‰ daucosterol, 16.93~19.39 wt‰ benzoyl-β-D-glucopyranoside, 2.89~3.61 wt% 2,8-triol-1-O-β-D-glucopyranoside, 2.732~2.848 wt‰ quercetin-3-O-α-D-arabinofuranoside and 13.56~17.14 wt‰ ferulic acid by weight per thousand, and viable Bacillus amyloliquefaciens powder not less than 100 million / g; Among them, the domestication culture includes domestication cultures carried out successively in a first domestication medium, a second domestication medium and a third domestication medium. The first domestication medium contains 18.0 g / L Jerusalem artichoke whole powder and 2.0 g / L notoginseng powder, the second domestication medium contains 10.0 g / L Jerusalem artichoke whole powder and 10.0 g / L notoginseng powder, and the third domestication medium contains 8.0 g / L Jerusalem artichoke whole powder and 12.0 g / L notoginseng powder.

2. A meal replacement powder, which is made of 0.0001~10 parts of the notoginseng active composition according to claim 1, 50~80 parts of soluble dietary fiber and other food-acceptable excipients.

3. Use of the notoginseng active composition according to claim 1 in the preparation of weight loss health products.

4. Use of the notoginseng active composition according to claim 1 in the preparation of lipid-lowering health products.

5. Use of the notoginseng active composition according to claim 1 in the preparation of a hypoglycemic health product.

6. Use of the meal replacement powder according to claim 2 in the preparation of a health product that facilitates the transformation of the intestinal microecology towards a probiotic direction.

Images